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To the Editor:
In recent Point/Counterpoint Editorials in CHEST (November 2010), Drs Celli and Halbert 1 argue in favor of and Drs Enright and Brusasco 2 argue against using the fi xed cutpoint for FEV 1 /FVC , 0.70 to defi ne airfl ow obstruction when diagnosing COPD. This is clearly an important debate, but we believe that the authors fail to address some essential points in their respective contributions.
They base their arguments mainly on issues related to other conditions (ie, hypertension), detection of obstruction in the general population, comparison of prevalence fi gures between countries, underdiagnosis of COPD, and population-level evidence regarding FEV 1 /FVC decline with age. 1 , 2 However, in our view, the debate about the preference for the 0.70 or an age-and sex-specifi c FEV 1 /FVC cutpoint should focus on the consequences of this choice when diagnosing individuals.
Primary care physicians (PCPs) are often the fi rst health-care professionals that people will turn to when they experience respiratory symptoms. Thus, in many cases it will be the PCP who needs to decide whether the symptoms are caused by COPD or by one of the many other causes for the patient's symptoms. 3 Availability of spirometry is indeed increasing in many countries, and PCPs will often need to interpret the spirometry results, even though they are not respiratory experts. By stating that "it is the evaluating physician who ultimately decides the medical signifi cance of an abnormal value in a specifi c patient encounter," Drs Celli and Halbert 1 do seem to recognize this, but at the same time they cast doubt on PCPs' ability to judge the signifi cance of an abnormal value for the FEV 1 /FVC ("It can be easily understood by clinicians, lowering some of the barriers to spirometry."). The best thing we can do to support PCPs in deciding whether an FEV 1 /FVC value is medically signifi cant in a particular patient is to provide them with cutpoints that leave no indefi niteness about the role age, sex, and race have in the interpretation of the patient's spirometry test. We have recently shown that using lower limit of normal (LLN) cutpoints instead of FEV 1 /FVC , 0.70 substantially reduces the number of false-positive interpretations in primary care, especially in elderly subjects ( Fig 1 ) . 4 We agree with Drs Enright and Brusasco 2 that switching to LLN cutpoints does not need to be that complicated, as most electronic spirometers already incor porate LLN equations, and even if they do not, a simple table or graphical aid-which is no more diffi cult to read than growth charts for children-could solve this.
From a research point of view, the million-dollar question is whether a middle-aged or elderly subject who has an LLN , FEV 1 /FVC , 0.70 when being evaluated for possible COPD actually shows abnormal progression of airfl ow obstruction or other clinical features that justify a COPD diagnosis. Currently, there is insuffi cient evidence to answer this question. We are very interested to learn the responses of the authors on these points.
Response
To the Editor:
I am happy that the Point/Counterpoint Editorial (November 2010) 1 , 2 have stirred interest in the medical community regarding the use of spirometry to defi ne COPD. In their letter, Drs Robberts and Schermer present support to both positions expressed in the Point/Counterpoint Editorials.
First, they agree that the health-care provider is the person who decides the clinical signifi cance of an observed test result, a central argument in our thesis. In this context, a cutoff value for any test serves only as a guide, as it does for all of the supportive tests in medicine. Even though the authors of the letter would like to avoid the comparison, how would they interpret a hemoglobin value of 12.9 mg/dL in a 75-year-old man? Would they label the patient as having anemia? Or, for that matter, an arterial BP of 140/90 mm Hg in an 82-year-old woman? In both instances, the health practitioner uses the clinical context to determine whether the test result supports (and I emphasize the word support) a clinical diagnosis. Agreed-upon operational defi nitions are by and large used in studies to avoid subjective misclassifi cation. In this regard, the simpler the defi nition, the more likely it will be accepted and shared.
Second, the authors of the letter support the argument presented by Enright and Brusasco 2 that the predictive value is better because it corrects the "overdiagnosis" in elderly subjects who would not have COPD. They base the argument on their study evaluating the value of spirometries in the diagnosis of COPD from The Netherlands. 3 That work used as reference predictive lung function values obtained from the European Community for Steel and Coal. 4 I ask, what about the large portions of the world where there are no predictive values for lung function? What are they to use? I believe that an agreed-upon ratio corrects for differences and provides clinicians everywhere with a practical tool for a disease that remains largely underdiagnosed. For the fourth-largest killer in the world, a simplifi ed operational defi nition can go a long way in simplify ing the approach to its eradication.
Bartolome R. Celli , MD, FCCP
Boston, MA
